Menu Search
Equities

Avanos Medical Inc

8HH:DUS

Avanos Medical Inc

Actions
  • Price (EUR)18.90
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change-1.05%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Avanos Medical Inc had net income fall from a gain of 50.50m to a loss of 61.80m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 47.73% to 49.26%.
Gross margin55.51%
Net profit margin3.18%
Operating margin4.92%
Return on assets1.28%
Return on equity1.77%
Return on investment1.45%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Avanos Medical Inc fell by 40.00m. However, the company earned 32.40m from its operations for a Cash Flow Margin of 4.81%. In addition the company generated 21.60m cash from investing, though they paid out 94.20m more in financing than they received.
Cash flow per share1.46
Price/Cash flow per share13.88
Book value per share26.76
Tangible book value per share4.67
More ▼

Balance sheet in USDView more

Avanos Medical Inc has a Debt to Total Capital ratio of 11.64%, a lower figure than the previous year's 21.14%.
Current ratio2.22
Quick ratio1.46
Total debt/total equity0.1317
Total debt/total capital0.1164
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.